Antibiotic prophylaxis and treatment of reactive arthritis: Lessons from an animal model

Arthritis and Rheumatism

Volumn 39, Issue 7, 1996, Pages 1238-1243

  Zhang, Yong ^a,b   Gripenberg Lerche, Christel ^a   Söderström, Karl Ove ^a   Toivanen, Auli ^a   Toivanen, Paavo ^a  

^a Turku University   (Finland)

^b TURKU UNIVERSITY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TISSUE LEVEL; MALE; MESENTERY LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; RAT; REACTIVE ARTHRITIS; SUBCUTANEOUS DRUG ADMINISTRATION; YERSINIA ENTEROCOLITICA;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBIOTIC PROPHYLAXIS; ARTHRITIS, REACTIVE; BODY WEIGHT; CIPROFLOXACIN; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FECES; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE ACTIVATION; MALE; RATS; RATS, INBRED LEW; SPECIFIC PATHOGEN-FREE ORGANISMS; YERSINIA ENTEROCOLITICA; YERSINIA INFECTIONS;

EID: 0029895620     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780390725     Document Type: Article

References (25)

1. Toivanen A: Reactive arthritis. In, Rheumatology. Edited by JH Klippel, PA Dieppe. London, Mosby, 1993
2. Toivanen A, Toivanen P: Epidemiologic aspects, clinical features, and management of ankylosing spondylitis and reactive arthritis. Curr Opin Rheumatol 6:354-359, 1994
3. Mason T, Fisher M, Kujala G: Acute rheumatic fever in West Virginia: not just a disease of children. Arch Intern Med 151:133-136, 1991
4. Lue HC, Wu MH, Wang JK, Wu FF, Wu YN: Long-term outcome of patients with rheumatic fever receiving benzathine penicillin G prophylaxis every three weeks versus every four weeks. J Pediatr 125:812-816, 1994
5. Leirisalo-Repo M: Treatment of reactive arthritis. Rheumatol Europe 24:20-22, 1995
6. Bardin T, Enel C, Cornelis F, Salski C, Jorgensen C, Ward R, Lathrop GM: Antibiotic treatment of venereal disease and Reiter's syndrome in a Greenland population. Arthritis Rheum 35: 190-194, 1992
7. Lauhio A, Leirisalo-Repo M, Lähdevirta J, Saikku P, Repo H: Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum 34:6-14, 1991
8. Lauhio A, Sorsa T, Lindy O, Suomalainen K, Saari H, Golub LM, Konttinen YT: The anticollagenolytic potential of lymecycline in the long-term treatment of reactive arthritis. Arthritis Rheum 35:195-198, 1992
9. Locht H, Kihlström E, Lindström FD: Reactive arthritis after Salmonella among medical doctors: study of an outbreak. J Rheumatol 20:845-848, 1993
10. Toivanen A, Yli-Kerttula T, Luukkainen R, Merilahti-Palo R, Granfors K, Seppälä J: Effect of antimicrobial treatment on chronic reactive arthritis. Clin Exp Rheumatol 11:301-307, 1993
11. Toivanen A, Merilahti-Palo R, Gripenberg C, Lahesmaa-Rantala R, Söderström KO, Jaakkola UM: Yersinia-associated arthritis in the rat: experimental model for human reactive arthritis? Acta Pathol Microbiol Immunol Scand (C) 94:261-269, 1986
12. Hill JL, Yu DTY: Development of an experimental animal model for reactive arthritis by Yersinia enterocolitica infection. Infect Immun 55:721-726, 1987
13. Merilahti-Palo R, Gripenberg-Lerche C, Söderström KO, Toivanen P: Long term follow up of SHR rats with experimental yersinia associated arthritis. Ann Rheum Dis 51:91-96, 1992
14. Gripenberg-Lerche C, Toivanen P: Yersinia associated arthritis in SHR rats: effect of the microbial status of the host. Ann Rheum Dis 52:223-228, 1993
15. Gripenberg-Lerche C, Skurnik M, Zhang L, Söderström K-O, Toivanen P: Role of YadA in arthritogenicity of Yersinia enterocolitica serotype O:8: experimental studies with rats. Infect Immun 62:5568-5575, 1994
16. Gripenberg-Lerche C, Skurnik M, Toivanen P: Role of YadA-mediated collagen binding in arthritogenicity of Yersinia enterocolitica serotype O:8: experimental studies with rats. Infect Immun 63:3222-3226, 1995
17. Easmon CSF, Crane JP: Uptake of ciprofloxacin by macrophages. J Clin Pathol 38:442-444, 1985
18. Easmon CSF, Crane JP, Blowers A: Effect of ciprofloxacin on intracellular organisms: in-vitro and in-vivo studies. J Antimicrob Chemother 18 (suppl D):43-48, 1986
19. Scholl H, Schmidt K, Weber B: Sensitive and selective determination of picogram amounts of ciprofloxacin and its metabolites in biological samples using high-performance liquid chromatography and photothermal post-column derivatization. J Chromatogr 416: 321-330, 1987
20. Toivanen A, Lahesmaa-Rantala R, Vuento R, Granfors K: Association of persisting IgA response with Yersinia-triggered reactive arthritis: a study on 104 patients. Ann Rheum Dis 46:898-901, 1987
21. De Koning J, Heesemann J, Hoogkamp-Korstanje JAA, Festen JJM, Houtman PM, van Oijen PLM: Yersinia in intestinal biopsy specimens from patients with seronegative spondyloarthropathy: correlation with specific serum IgA antibodies. J Infect Dis 159:109-112, 1989
22. Wagner SJ, Friedman LI, Dodd RY: Transfusion-associated bacterial sepsis. Clin Microbiol Rev 7:290-302, 1994
23. Toivanen A, Toivanen P: Aetiopathogenesis of reactive arthritis. Rheumatol Europe 24:5-8, 1995
24. Viitanen AM, Arstila TP, Lahesmaa R, Granfors K, Skurnik M, Toivanen P: Application of the polymerase chain reaction and immunofluorescence techniques to the detection of bacteria in Yersinia-triggered reactive arthritis. Arthritis Rheum 34:89-96, 1991
25. Nikkari S, Merilahti-Palo R, Saario R, Söderström K-O, Granfors K, Skurnik M, Toivanen P: Yersinia-triggered reactive arthritis: use of polymerase chain reaction and immunocytochemical staining in the detection of bacterial components from synovial specimens. Arthritis Rheum 35:682-687, 1992